Gandara DR, Von Pawel J, Sullivan RN, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001).
TIL-therapie gecombineerd met anti-PD-1 bij gemetastaseerd huidmelanoom: hoopvolle resultaten
jun 2023 | Dermato-oncologie, Immuuntherapie